NCT03730129View on ClinicalTrials.gov

Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

July 3, 2020

Study Completion Date

July 3, 2020

Conditions
Secondary Immune Deficiency Disorder
Interventions
DRUG

Hizentra

Subjects will receive Hizentra 0.4 mg/kg qweekly subcutaneously for 6 months (24 weeks)

Trial Locations (1)

14607

Allergy, Immunology, Rheumatology at Rochester Regional Health, Rochester

All Listed Sponsors
lead

Rochester General Hospital

OTHER

NCT03730129 - Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig | Biotech Hunter | Biotech Hunter